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Abstract
Background: The management of stage IV colorectal cancer with liver metastases has historically
involved a multidisciplinary approach. In the last several decades, there have been great strides
made in the therapeutic options available to treat these patients with advancements in medical,
surgical, locoregional and adjunctive therapies available to patients with colorectal liver
metastases(CLM). As a result, there have been improvements in patient care and survival.
Naturally, the management of CLM has become increasingly complex in coordinating the various
aspects of care in order to optimize patient outcomes.
Review: A review of historical and up to date literature was undertaken utilizing Medline/PubMed
to examine relevant topics of interest in patients with CLM including criterion for resectability,
technical/surgical considerations, chemotherapy, adjunctive and locoregional therapies. This review
explores the various disciplines and modalities to provide current perspectives on the various
options of care for patients with CLM.
Conclusion: Improvements in modern day chemotherapy as allowed clinicians to pursue a more
aggressive surgical approach in the management of stage IV colorectal cancer with CLM.
Additionally, locoregional and adjunctive therapies has expanded the armamentarium of treatment
options available. As a result, the management of patients with CLM requires a comprehensive,
multidisciplinary approach utilizing various modalities and a more aggressive approach may now be
pursued in patients with stage IV colorectal cancer with CLM to achieve optimal outcomes.
Introduction
Colorectal cancer(CRC) is the third most common noncu-
taneous malignancy in both men and women(Men -
Lung, Prostate; Women - Lung, Breast) [1]. Approximately
150,000 cases of colorectal cancers are diagnosed annu-
ally in the United States, 25% of which present with liver
metastases [2]. In total, up to one-half will develop liver
metastases. The management of colorectal liver metas-
tases (CLM) has changed dramatically in the last decade as
a result of significant improvements in both medical and
interventional therapies now offered. With improvements
in therapy come increasing challenges to surgeons and
oncologists as to the optimal management of CLM.
Patients with CLM require a comprehensive multimodal-
ity treatment approach, but surgical resection does remain
the mainstay of curative therapy. In the era of 5-Fluorour-
acil, achievement of ten-year survivals of 17-25% after
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attempted curative hepatectomy were encouraging [3].
However, the importance of surgical intervention for cur-
ative therapy was particularly evident in a study by Scheele
et al. demonstrating improved survival following hepate-
ctomy for CLM compared to patients with unresectable
disease and to patients with resectable disease that did not
undergo operation [4]. In the group undergoing poten-
tially curative resection, five- and ten-year actuarial sur-
vival of 40% and 27% were achieved, respectively. In
contrast, median survivals of 6.9 months and 14.2
months without any five-year survivors were seen in the
unresectable group and the nonoperative group with
resectable disease, respectively. Unfortunately, only 10-
20% of patients with colorectal liver metastases are actu-
ally resection candidates. However, of those patients ame-
nable to resection, five-year survivals of over 50% are
possible, despite recurrences being common [5-7].
Advances in systemic chemotherapy and targeted biologic
therapy are occurring at a rapid rate with multiple trials
demonstrating encouraging results compared to historical
data with increased median survivals of approximately 20
months for patients with unresectable disease [8,9]. How-
ever, a thorough discussion of completed and ongoing tri-
als for chemotherapy is beyond the scope of this review.
Herein, we will focus on the surgical aspects of the man-
agement of CLM and restrict discussion of chemothera-




Traditional dogma governing surgical intervention
restricted hepatectomy for colorectal liver metastases to
patients with unilobar disease, less than four lesions,
lesions less than five centimeters in greatest dimension,
and those without extrahepatic disease. However, with
improvement in surgical techniques and advancements in
systemic therapy using a multidisciplinary approach,
focus has shifted towards the amount of residual liver
after resection, or the future liver remnant (FLR). As such,
tumor-related factors are no longer considered absolute
contraindications to surgical resection, although they are
still harbingers of more aggressive tumor biology [10-12].
Historically, these characteristics of the primary tumor
and CLM have been utilized to determine the risk of recur-
rence after curative hepatectomy.
Fong et al. examined this concept closely and created a
clinical risk score(CRS) using regression analysis in exam-
ining multiple clinical factors of 1001 patients that under-
went hepatectomy for CLM [13]. Fong et al. found five
clinical criteria that were prognostic for patient outcome.
These included node-positive primary, carcinoembryonic
antigen(CEA) greater than 200 ng/mL, greater than one
liver lesion, any lesion greater than five centimeters, and
disease free interval less than one year from resection of
the primary lesion. These five clinical criteria were imple-
mented into a CRS which may be utilized preoperatively
as a prognostic indicator of long-term outcome and hence
aid in patient selection.
In 2006, the American Hepato-Pancreato-Biliary Associa-
tion (AHPBA), Society of Surgical Oncology (SSO), and
Society for Surgery of Alimentary Tract (SSAT) convened
for a consensus conference to examine many of the issues
regarding indications for hepatectomy for CLM [14]. Rec-
ommendations put forth by this panel focused on the
ability to obtain margin-negative resection while leaving a
FLR consisting of at least two contiguous hepatic sectors,
adequate inflow, outflow, biliary drainage, and a greater
than 20% FLR of liver volume in a healthy liver.
Impact of Margin Status
The importance of margin status after resection has been
discussed and studied in which multiple studies have
demonstrated improved disease-free and overall sur-
vival(OS) in patients who underwent margin negative
resections. Choti et al. demonstrated that those patients
with positive margin resection had survival of 24 months
versus 46 months in those with negative margins [15].
Likewise, Pawlik et al. demonstrated decreased OS with
higher local recurrence rates for those with positive mar-
gin resection [7]. Interestingly, in a subgroup analysis,
Pawlik's study demonstrated that the previously thought
resection margins of at least one centimeter did not dem-
onstrate a statistically significant difference in recurrence
rate, site of recurrence, or OS relative to those patients
with close (i.e. 1 - 4 mm) margins. This led the SSO con-
sensus group to conclude that, while wide margins of least
one centimeter should be sought, anticipation of a close
margin should not preclude resection [14].
Interestingly, with the improvement in response rates
with modern day chemotherapy, recent studies are reex-
amining the requirement of margin negative resection to
achieve improved outcomes. Recently, de Haas et al.
examined 436 patients of which 234 underwent R0 resec-
tion while 202 patients underwent R1 resection [16]. The
R1 resection group, not unexpectedly had a higher
number and size of CLM often with bilobar disease which
made safe negative margin resections prohibitive. Inter-
estingly, the five-year OS rate was 60% and 57% for R0
and R1 resection, respectively(p = 0.27). Five-year disease
free survival(DFS) was 29% and 20% for R0 and R1 resec-
tion, respectively(p = 0.12). However, when examining
intrahepatic recurrence, a significant difference was
observed with a higher recurrence of 28% associated with
R1 resection versus 17% for R0 resection.(p = 0.004) This
study also determined poor independent predictors forWorld Journal of Surgical Oncology 2009, 7:72 http://www.wjso.com/content/7/1/72
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OS included CEA>10 ng/ml and major hepatectomy. Fac-
tors that were poor predictors for positive margin resec-
tion included intraoperative blood transfusions, bilobar
disease, and CLM > 3 cm. Therefore, it appears that R1
resection is associated with a higher recurrence rate, how-
ever, with improving chemotherapy, survival with R1
resection appears similar to R0 resection and may sub-
stantiate an aggressive surgical approach to treatment of
CLM even with questionable ability to achieve margin-
negative resection and may no longer be an absolute con-
traindication to attempted curative resection in highly
selected patients.
Extrahepatic Disease
The presence of extrahepatic disease (EHD) has tradition-
ally been thought of as an absolute contraindication to
hepatectomy for CLM, however there is increasing discus-
sion in the literature questioning this. As illustrated in
Table 1, over the last two decades, there have been multi-
ple studies demonstrating reasonable survival rates in
selected patients with EHD that were treated with an
aggressive surgical approach. Additionally, studies have
examined the question of EHD as a whole and in terms of
sites of EHD specifically(e.g. pulmonary, portal adenopa-
thy, peritoneal) [11,17-19]. There is increasing support
arguing for a paradigm shift from an absolute contraindi-
cation to hepatectomy in the presence of EHD to use of
hepatectomy combined with resection of EHD in highly
selected patients.
Elias et al. retrospectively examined 376 patients who
underwent hepatectomy for CLM, of which 111 (30%)
underwent resection of various foci of EHD [18]. While
five-year OS between patients without and with EHD was
34% and 20%, respectively, outcome was dependent
upon the distribution of EHD as well as the complete
resection of all EHD. Of the 111 patients with EHD, an R0
resection was achieved in 77 (69%) while 34 (31%) had
incomplete (i.e. R1 or R2) resection. When complete (i.e.
R0) resection was possible, five-year survival was 29% in
those with EHD compared to 38% for those without
EHD(p = 0.072). These results when compared to those
patients who historically received chemotherapy alone
demonstrated more favorable outcomes [18].
In a retrospective study by Carpizo et al., 1369 patients
with CLM that underwent resection were examined, 127
of which had concurrent EHD resected at the time of
hepatectomy [20]. Patients with EHD had worse three-
and five-year survival rates(47% and 26%, respectively)
compared to those patients without EHD(67% and 49%,
respectively)(p < 0.001). Additionally, multivariate analy-
sis revealed four factors that were independently associ-
ated with worse survival including CRS ≥ 3, EHD detected
intraoperatively, incomplete resection of EHD, and neo-
adjuvant chemotherapy. However, recurrence in the EHD
group was almost inevitable seen in 110/116(95%)
patients.
Another topic of consideration with relation to EHD that
continues to be discussed is extrahepatic lymph node dis-
ease. Regional lymph node disease traditionally has been
thought to be a poor prognostic indicator with relation to
patient outcome and considered a contraindication to
liver resection. More recently, this has been questioned
and Adam et al. recently examined the results of 763
patients who received preoperative chemotherapy of
which 47 then underwent hepatic metastasectomy with
simultaneous lymphadenectomy [21]. Five-year OS of
11% and 23% were seen in patients with lymph node
involvement and without lymph node involvement(p =
0.004), respectively. Of particular importance on further
analysis was lymph node location. Observed five-year OS
was 25% for hepatic pedicle nodes versus 0% for celiac
and para-aortic lymph nodes(p = 0.001). Multivariate
analysis determined that celiac node involvement and age
Table 1: Five-year Overall Survival of patients with EHD undergoing hepatic resection for CLM.
Study Year # of Patients Patients with EHD(% of total) 5 year Overall Survival of patients with EHD(%)
Scheele et al [11]. 1995 469 47(10) 26
Fong et al [13]. 1999 1001 43(4) 18
Minagawa et al [97]. 2000 235 17(7) 21
Elias et al [18]. 2003 376 111(29) 20
Elias et al [19]. 2005 308 84(27) 28
Carpizo et al [20]. 2009 1369 127(9.3) 26
Six large studies in the past two decades that examined the significance of EHD and the overall 5-year survivals in patients with CLM that 
underwent hepatic resection.World Journal of Surgical Oncology 2009, 7:72 http://www.wjso.com/content/7/1/72
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≥ 40 were independent poor prognostic indicators. Adam
et al. concluded that in well selected patients with disease
responsive to chemotherapy, simultaneous hepatic resec-
tion with pedicular lymphadenectomy is reasonable. Sim-
ilarly, Oussoultzoglou et al. examined 45 patients with
CLM and pathologically proven hepatic lymph nodes
[22]. In their analysis, the node location was divided into
2 areas. Area 1 comprised proximal adenopathy within
the hepatoduodenal ligament and retroduodenopancre-
atic zones. Area 2 was comprised of distal adenopathy
involving common hepatic artery and celiac axis. Overall
3-year and 5-year survival rates were 29.7% and 17%,
respectively. In sub-analysis, area 1 median 3-year and 5-
year survivals were 34.3% and 25.7%, respectively versus
30.1% and 16.7% for area 2(p = 0.7755). This study sup-
ports the concept that with modern day chemotherapy, it
may be beneficial to pursue an aggressive curative
approach and to extirpate sites of hepatic disease and
EHD including lymph nodes. Additional support for an
aggressive approach in patients with distant, resectable
EHD has also been demonstrated by de Haas et al. in
which they pursued sequential resection of various distant
disease sites with reasonable outcomes with five-year sur-
vivals over 30% [23].
Hence, in patients with good response to chemotherapy,
it is reasonable in highly selected patients to pursue a safe,
aggressive surgical approach to extirpate various sites of
disease inclusive of regional lymph nodes and sites of dis-
tant, resectable disease.
Multifocal Disease
Early experiences with resection for CLM reported the
presence of greater than four lesions as a harbinger of
poor outcome and a contraindication to resection
[10,24,25]. These early reports were often confounded by
poor surgical outcomes for more complex operations. For
some time, the cutoff for resection was held at four
lesions, but recently, larger centers have begun to report
positive experiences with resection of multiple lesions and
this dogma may not hold true as surgical technique and
adjuncts improve. Pawlik et al. reviewed 159 patients with
four or more CLM (median 5, range 4-14) who underwent
curative resection with median survival of 62 months and
a five-year survival of 51% [26]. As well, Kornprat et al.
reported median survival of 44 months and five-year sur-
vival of 33% in 98 patients with resection of four or more
(median 5, range 4-15) CLM [27]. These results lend sup-
port that the number of CLM should no longer be an
absolute contraindication and a more aggressive
approach may be taken in selected patients.
Bilobar Disease
The presence of bilobar disease is traditionally one of the
most concerning characteristics in patients with CLM
being considered for hepatectomy. However, this concern
has not been substantiated with data. In fact, in assessing
10-year survival following curative hepatectomy, Tomlin-
son et al examined 612 patients of which 25% presented
with bilobar disease and investigated multiple preopera-
tive prognostic factors to assess survival and found that
bilobar disease did not preclude long-term survival and
cure [3].
Bolton et al reported on 121 patients with CLM who
underwent "simple" resections compared to 44 who had
"complex" resections of which 98% had bilobar metas-
tases [28]. Complex resections did not result in signifi-
cantly higher perioperative mortality compared to simple
resections (9% vs. 5%, respectively) nor did they signifi-
cantly reduce five-year OS (37%, median 39 ± 11 months
versus 36%, median 43 ± 4 months, respectively) suggest-
ing that an aggressive or "complex" approach is reasona-
ble in well selected patients.
Fong et al. reviewed 1001 patients who underwent hepa-
tectomy for CLM of which 40% were noted to have bilo-
bar disease [13]. Though, bilobar disease did represent an
adverse predictor of outcome compared to unilobar dis-
ease with five-year survivals of 29% and 38%(p = 0.02),
respectively, bilobar disease was not a predictor of poor
outcome and recurrence by multivariate analysis as
opposed to the five factors associated with Fong's CRS dis-
cussed previously. Hence, the CRS used for prognosis of
outcome and patient selection does not include bilobar
disease and survivals are favorable to justify pursuing a
surgical approach in highly selected patients with bilobar
disease.
Technical Considerations
At the heart of the expansion of indications for hepatec-
tomy for CLM has been a decrease in the perioperative
morbidity and mortality associated with major hepatec-
tomy in the modern era. Over the last two decades, we
have seen improvement in surgical techniques to opti-
mize the safety and outcomes of surgical resection. Better
understanding of the internal anatomy of the liver as
described by Couinaud in the 1950's clarified segmental
hepatic anatomy. This knowledge, combined with the use
of intraoperative ultrasound, has allowed for intraopera-
tive mapping of the vascular anatomy and tumor relation-
ships to optimally plan surgical resections, thus
minimizing morbidity and mortality. Other important
components to minimize the mortality and morbidity of
hepatic resection include the use of low central venous
pressure(CVP) anesthesia. Melendez et al. examined this
concept in the 1990's in which 496 patients underwent
low CVP hepatic resections [29]. There were no intraoper-
ative deaths with perioperative mortality rate of 3.8%,
median blood loss of 645 mL, and no transfusions neces-World Journal of Surgical Oncology 2009, 7:72 http://www.wjso.com/content/7/1/72
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sary in 67% of patients. Low CVP allowed safe resection
by minimizing blood loss and mortality without detri-
mental effects on renal or hepatic function and has been
further corroborated in other studies [30,31].
Synchronous Disease
The management of the primary tumor and synchronous
liver metastases remains an interesting challenge. Various
approaches have been described including concomitant
primary and metastases resection, as well as staged
approaches.
There has been historical concern regarding synchronous
resections of colorectal primaries and the hepatic metas-
tases with mortalities as high as 17% being reported [28].
As a result, there has been apprehension to this approach
prompting multiple studies examining the safety of a syn-
chronous versus staged approach.
The largest study, by Reddy et al., examined 610 patients
with stage IV CRC with CLM, of which 135 underwent
concomitant hepatectomy and primary colorectal resec-
tions and 475 underwent staged resections [32]. Simulta-
neous resection was associated with fewer (median 1
versus 2, p = 0.01) and smaller (median 2.5 versus 3.5 cm,
p = < 0.0001) metastases. Fewer simultaneous resection
patients underwent major (≥ 3 segments) hepatectomies
compared to staged resections(26.7% versus 61.3%, p <
0.05). Hospital stay was shorter after simultaneous resec-
tions compared to the cumulative hospitalization for
staged resections (median 8.5 vs. 14 days, p < 0.0001).
Importantly, the mortality (1.0% versus 0.5% for simulta-
neous and staged, respectively) and severe morbidity
(14.1% versus 12.5% for simultaneous and staged, respec-
tively) were similar after simultaneous colorectal resec-
tion with minor hepatectomy compared to minor
hepatectomy alone (both p > 0.05). This suggests that the
colon resection did not contribute adversely to outcome.
However, with major hepatectomy, comparisons of
simultaneous colorectal resection to staged resection
patients(does not include patients with staged resections
at different institutions) resulted in increased mortality
(8.3% versus 1.4%, p < 0.05) and severe morbidity
(36.1% versus 15.1%, p < 0.05). Reddy et al. also
addressed the confounding variable of different institu-
tions in an additional sub-analysis examining patients
undergoing major hepatectomy with simultaneous resec-
tion demonstrating greater severe morbidity compared to
single institution staged resections(36.1% versus 17.6%, p
= 0.05), but was similar among patients undergoing
minor hepatectomy (14.1% versus 10.5%, p > 0.05).
Hence, major hepatectomy appears to independently pre-
dict severe morbidity after simultaneous resections [haz-
ard ratio (HR) = 3.4, p = 0.008]. The validity of this data
may be questioned secondary to the fact that only 14.7%
of staged patients underwent staged resections at a single
institution. As such the reported morbidity may underes-
timate the associated total morbidity secondary to inade-
quate data capture. The authors concluded that
synchronous resection with simultaneous minor hepatec-
tomy is safe with shorter hospital stay. However, synchro-
nous resection with major hepatectomy should be
performed only in highly selected patients so as to mini-
mize associated morbidity and mortality.
More recently, Martin et al. examined 230 patients, of
which 70 underwent simultaneous colorectal/hepatic
resection versus 160 patients who underwent staged resec-
tions [33]. In this study, simultaneous versus staged oper-
ations were similar for major hepatic resections
performed(≥ 3 Couinaud segments)(32% vs. 33%), size
of hepatic metastases (4 cm vs. 3.7 cm), and number of
hepatic metastases(3 vs. 3), respectively. Complication
rates and severity were also similar between groups(55%
vs. 56%), respectively. As may be expected, the simultane-
ous group had a shorter length of stay compared to the
cumulative length of stay in the staged group (10 days vs.
18 days, respectively, p = 0.001). The authors concluded
that simultaneous resection remains an acceptable option
for those patients with synchronous disease with similar
mortality and morbidity and a decreased length of hospi-
tal stay.
When considering a staged approach to synchronous
CLM, the order of resection is worthy of discussion. Tradi-
tionally, the primary tumor has been addressed initially
followed by treatment of liver disease. There has been his-
torical concern regarding the potential complications
associated with the primary tumor including perforation,
bleeding, and obstruction that led to a dogmatic primary-
first approach followed by management of liver disease.
Increasingly, a liver first approach has been explored.
Scoggins et al. retrospectively examined 89 patients with
synchronous CLM to determine the impact of the man-
agement of the primary tumor on morbidity and survival
[34]. Sixty-six patients underwent resection of the pri-
mary, while 23 patients with an asymptomatic primary
received chemotherapy, external beam radiotherapy or
combined chemoradiation. The median survival was sim-
ilar between those who underwent surgical and non-sur-
gical management of their primary(14.5 months vs. 16.6
months, respectively, p = 0.059). The operative group had
a perioperative morbidity rate of 30.3% and mortality rate
of 4.6%. The nonoperative group had a surgery-free sur-
vival of 91.3% with two patients(8.7%) ultimately requir-
ing emergent diversion secondary to obstruction. No
complications of perforation or bleeding occurred in the
nonoperative group. This study suggests that it is not nec-World Journal of Surgical Oncology 2009, 7:72 http://www.wjso.com/content/7/1/72
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essary to first address the primary tumor prior to interven-
tion for CLM.
Mentha et al. corroborates a liver first approach in which
they treated 35 patients with chemotherapy initially fol-
lowed by liver resection and then treatment of the primary
tumor [35]. Five patients were unable to complete treat-
ment (one chemotherapy-related sepsis, one complete
response of liver metastases, three with progression).
Three- and five-year survival rates of the remaining 30
patients were 60% and 31%, respectively with overall
median survival of 44 months. This approach was also
supported in other studies by Poultsides et al. and Puthil-
lath et al in which asymptomatic patients with stage IV
CRC were safely treated with up front chemotherapy and
deferral of surgery [36,37]. Hence, it is reasonable to pur-
sue a liver-first approach in patients with asymptomatic
primary tumors using nonoperative management of the
primary with low risk of complications and no statistically
significant adverse effect on survival, while minimizing
the risk of CLM disease progression during treatment of
the primary.
Portal Vein Embolization
Paramount in devising hepatectomy to allow complete
extirpation of all disease is leaving adequate FLR to pre-
vent postoperative hepatic insufficiency. In patients with
an anticipated inadequate FLR or when regeneration is
likely to be impaired, such as in the face of cirrhosis or
chemotherapy-induced steatohepatitis, initiation of the
regeneration process prior to hepatectomy potentially
reduces the risk of postoperative hepatic insufficiency.
Portal vein embolization (PVE) was first described in
1990 by Makuuchi as a means to hypertrophy the FLR
prior to liver resection [38]. This approach employs pre-
operative embolization of the portal vein to all tumor-
bearing liver, thus allowing hypertrophy of the contralat-
eral FLR [39]. It is necessary to assess the FLR relative to
total liver volume to determine the need for PVE. The
FLR(%) may be calculated by employing radiographically
obtained FLR volumetry, as well as established formulas
for total liver volume(TLV) and body surface area(BSA).
The FLR(%) is calculated using the formula: FLR(%) =
FLR(radiographic volumetry, cm2)/TLV. The FLR(volume-
try) is determined by obtaining an estimated radiographic
absolute volume(cm2) of the FLR using computed tomog-
raphy(CT) with three dimensional reconstructions(3-D).
The total liver volume is obtained using the formula:
TLV(cm3) = 706 + BSA(m2) + 2.4 [40]. BSA may be calcu-
lated using the Mosteller formula: BSA(m2) =
([Height(cm) × Weight(kg)]/3600)1/2. In those patients
with normal underlying liver where the FLR is anticipated
to be <20%, PVE prior to extended hepatectomy poten-
tially minimizes postoperative morbidity. In patients with
cirrhotic/fibrotic livers, as well as those who have had
extensive chemotherapy where the FLR is <30%, PVE
should also be considered [41].
PVE has been a useful adjunct to increase the pool of
potential resection candidates. Abdalla et al. examined 42
patients planned for extended right hepatectomy [42].
Groups were divided into 18 patients that underwent PVE
compared to 24 who did not. In normal circumstances,
patients subjected to PVE would not have been offered
resection for fear of postoperative liver failure. In those
undergoing preoperative PVE, the FLR increased from
18% to 25%. No significant difference between groups
was seen for morbidity and mortality. The overall three-
year survival was 65% with statistically similar median
survival of 40 vs. 52 months for PVE and no PVE, respec-
tively. As a result, PVE enabled safe and potentially cura-
ble resection in patients who were otherwise not deemed
surgical candidates. Whether there is any oncologic effect
of preoperative PVE is yet to be determined. Current rec-
ommendations are for PVE to be undertaken in patients
with otherwise normal livers when FLR is less than 20%,
in patients with steatohepatitis or steatosis due to chemo-
therapy or other etiology when FLR is less than 30%, and
in patients with severe fibrosis or cirrhosis when FLR is
less than 40%. An increase in FLR can be seen 4-6 weeks
following PVE suggesting that the liver is capable of regen-
eration and has typically attained adequate volume to
proceed with surgical intervention with the hope of mini-
mizing postoperative hepatic insufficiency. This is well
CLM with Small FLR Prior to Hepatic Resection Figure 1
CLM with Small FLR Prior to Hepatic Resection. 
Patient with metastatic rectal carcinoma with right hepatic 
metastasis who was an operable candidate for right hepatec-
tomy, but on preoperative computed tomography(CT; 5/12/
09), the patient had a small left hepatic lobe and FLR.World Journal of Surgical Oncology 2009, 7:72 http://www.wjso.com/content/7/1/72
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illustrated in examining the FLR growth from figure 1 to
figure 2. Additional radiographic 3-D reconstructions in
figure 3 and 4 demonstrate calculated FLR volumes and
illustrate the growth after PVE that may be achieved prior
to hepatic resection
Two-Stage Hepatectomy
Patients with CLM have traditionally been classified as
"resectable" or "unresectable" largely based on technical
considerations. Unresectable patients with bilobar disease
are not safely able to have their tumors completely
resected at one operation, even in patients with low vol-
ume tumor burden. However, a third group of patients
has now arisen, the "sub-optimally resectable." These
patients typically have multifocal bilobar disease in which
the management of these patients is complex. These
patients often receive chemotherapy given the extent of
disease and this is valuable in patient selection because
chemotherapy may aid in downsizing tumor burden as
well as determine patient tumor biology that would in fact
benefit from an aggressive surgical approach. With adju-
vants to surgery including ablative therapy and PVE, dif-
ferent strategies have been devised to achieve extirpation
multifocal bilobar disease using a two-stage approach.
One of the major questions with regards to two-stage
hepatectomy is how and in what order to address bilobar
disease.
CLM after PVE for Small FLR Prior to Hepatic Resection Figure 2
CLM after PVE for Small FLR Prior to Hepatic 
Resection. Patient(as in Figure 1) with metastatic rectal car-
cinoma and right hepatic metastasis who underwent right 
PVE(6/10/09) with followup CT(7/13/09) with demonstrable 
growth of the FLR.
Three Dimensional(3-D) Reconstruction of Small FLR with  calculated volume measurements Figure 3
Three Dimensional(3-D) Reconstruction of Small 
FLR with calculated volume measurements. Patient(as 
in Figure 1, 2) with metastatic rectal carcinoma and right 
hepatic metastasis with small FLR with radiologically calcu-
lated volume of 325.9 cm2. Using standardized volumetric 
formulas, this patient had a FLR of approximately 19%.
3-D Reconstruction of FLR after Right PVE for Small FLR Figure 4
3-D Reconstruction of FLR after Right PVE for Small 
FLR. Patient(as in Figures 1, 2, and 3) with metastatic rectal 
carcinoma and right hepatic metastasis with small FLR(19%) 
that underwent right PVE with good response and growth of 
left hepatic lobe with calculated FLR volume of 528.5 cm2. 
The FLR after PVE was approximately 31%.World Journal of Surgical Oncology 2009, 7:72 http://www.wjso.com/content/7/1/72
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In an early series, Adam et al first described their experi-
ence with staged hepatectomy in 16 patients with "unre-
sectable" bilobar CLM [43]. The hepatic tumor burden is
typically more predominant on the right side. Hence, the
initial operation consisted of a right hepatectomy address-
ing the more significant tumor burden and without inci-
dence of perioperative mortality. Following left liver
regeneration after the initial resection, 13 patients under-
went repeat resection for the residual left sided disease,
eight of which were major hepatectomies with two result-
ing perioperative deaths. Three patients did not undergo a
second stage resection secondary to disease progression
between procedures, one with intrahepatic progression
and two with extrahepatic progression. All patients
received chemotherapy before and after hepatectomy.
Median OS was 31 months from the second hepatectomy
and 44 months from the initial diagnosis of liver metas-
tases. Four patients developed hepatic recurrence, of
which three underwent a third resection. This early work
examining two stage hepatectomy demonstrated need for
careful surgical planning with inherent risk of morbidity
and mortality in these patients. Theoretical advantage to
this approach is that at the initial stage, a majority of
tumor burden is addressed with benefit of FLR regenera-
tion. However, one must consider that this approach has
a more extensive initial operation resulting in more tedi-
ous and difficult dissection at the time of the second stage
operation. Additionally, there is theoretic exposure of left
sided metastases to growth factors associated with hepatic
regeneration and could lead to increased growth rate of
the existing tumor burden.
Alternatively, Adam et al. further examined a staged
approach in which the left sided hepatic tumor burden
was addressed initially and occasionally in conjunction
with a right PVE [44]. PVE may be an important adjunct
in patients with bilobar disease requiring two stage
approach to promote hepatic regeneration of the FLR
when necessary. PVE allows for hypertrophy of the FLR in
which the disease has been cleared, thus allowing for a
second stage procedure (e.g. hemihepatectomy or
extended hepatectomy) in a reported 75.7% of patients
resulting in one- and three-year survivals of 70% and
54.4%, respectively [45,46]. Following regeneration of the
left lobe when right PVE was performed, a right hepatec-
tomy was then performed to complete extirpation of
hepatic disease. Obviously, in this approach, patients
must have a limited tumor burden on the left requiring
limited resection in order to allow for an adequate FLR
and subsequent regeneration. PVE was employed in 20
patients to aid in hepatic regeneration. Adam et al. had
31/45(69%) patients completed the planned two stage
hepatectomy in which 23 underwent left side initial
approach and the remaining 8 patients underwent right
hepatectomy initial approach. Multiple studies demon-
strated completion of two stage approach ranging from
76%-100% and second stage procedures often deferred
secondary to disease progression [44,45,47-49]. In com-
paring both approaches, Adam et al. found no significant
difference in complications, operative times, or blood
loss. The second stage procedure carried greater associated
morbidity and mortality. General complications were
6.5% and 22.6% for first and second stage, respectively.
Likewise, liver related complications were 12.9% and
48.4% for first and second stage, respectively. Second
stage procedures carried longer operative time, increased
blood loss, hospital stay, vascular clamping time.
Two(6.5%) perioperative mortalities were seen after the
second operation. It appears evident that hepatic reopera-
tion carries significant morbidity and mortality regardless
of approach. However, regardless of approach, favorable
outcomes were obtained with actuarial 3-year and 5-year
survival of 47% and 28%, respectively with median sur-
vival of 35 months. Fifteen(48.4%) patients developed
hepatic recurrence of which eight patients underwent
reoperation. A left sided first approach facilitates clearance
of left sided hepatic disease prior to PVE thereby eliminat-
ing the theoretical exposure of tumor to growth factors
that may perpetuate growth after a PVE. Additionally, an
initial procedure addressing left sided hepatic disease will
likely require less extensive dissection and thereby facili-
tate an easier dissection at the time of a second, often
more involved operation.
Jaeck et al also examined 33 patients with "unresectable"
CLM in which major hepatectomy was undertaken at the
second operation five to eight weeks following a minor
hepatectomy combined with interval right PVE(± Couin-
aud segment IV) was performed [45]. Second hepatec-
tomy was able to be accomplished in 28 patients with no
perioperative mortality. Five patients had disease progres-
sion prior to the second operation. Three-year OS follow-
ing two-stage hepatectomy was 54%.
With the improvements in modern day chemotherapy,
two-stage hepatectomy has become a viable option for
those patients that were previously considered "unresect-
able" for multifocal, bilobar disease. Now patients that
are responsive to chemotherapy may be considered "sub-
optimally resectable" and should be considered for an
aggressive surgical approach in a multidisciplinary tertiary
care setting.
The Impact of Chemotherapy on Hepatectomy
Chemotherapy may have had the biggest impact on the
approach to management of CLM. A decade ago, chemo-
therapy options were limited to traditional therapy with
fluorouracil(5-FU) and leucovorin. With the emergence of
newer cytotoxic(e.g. oxaliplatin, irinotecan) and bio-
logic(epidermal growth factor receptor(EGFR) and vascu-World Journal of Surgical Oncology 2009, 7:72 http://www.wjso.com/content/7/1/72
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lar endothelial growth factor(VEGF) inhibitors) agents,
multiple options are now available. The timing of chemo-
therapy has been debated as to whether neoadjuvant,
perioperative, or adjuvant therapy is optimal for those
patients with CLM.
Alberts et al. examined 42 patients with unresectable CLM
treated with a median six months of FOLFOX4 neoadju-
vant chemotherapy. Radiologic response was seen in
25(60%) patients including one complete response. Fol-
lowing response to therapy, 17(40%) patients proceeded
to surgery with 14 patients able to have complete resec-
tion, one with partial resection, and two still being consid-
ered unresectable. This conversion to resectable disease
resulted in a median survival of 26 months [50].
Recently, the European Organization for Research and
Treatment of Cancer (EORTC; Nordlinger et al.) asserted
there is potential benefit to the use of perioperative chem-
otherapy in those patients who are initially resectable
demonstrating increased progression-free survival(PFS)
over those patients who underwent surgery alone (35.4%
vs. 28.1%, respectively; p = 0.058) [51]. Additionally, in
another study by Nordlinger et al.(Eastern Cooperative
Oncology Group - ECOG), they examined neoadjuvant
chemotherapy and its use in all patients regardless of ini-
tial resectability status because it improved complete
resection rate, limited extent of resection, assessment of
tumor biology and response to chemotherapy. Four other
studies support the conclusions of the EORTC study sup-
porting the use of chemotherapy as a bridge to resectable
disease in the subset of patients who are initially unresect-
able [51-55].
With the improvement in response rates, survival, and the
ability to downsize unresectable CLM with modern day
chemotherapy, it has become necessary to also acknowl-
edge the associated toxicities when employing them as a
part of a multimodality approach [56-60]. With oxalipla-
tin treatment, there has been demonstration of hepatic
sinusoidal obstruction that increases with prolonged
treatment(i.e. greater than six cycles) [59]. The sinusoidal
obstruction syndrome(SOS) is a veno-occlusive phenom-
enon that has historically been associated with bone mar-
row transplantation. However, as oxaliplatin use has
became more prevalent, there is note of increased associ-
ation with SOS compared to other chemotherapy regi-
mens. Vauthey et al. demonstrated sinusoidal dilatation
with oxaliplatin that was five times more than that with
irinotecan therapy(19 vs. 4%, respectively) [57]. Grossly,
this is demonstrated by a 'blue liver' that is secondary to
trapped erythrocytes within the hepatic sinusoids. Vau-
they et al. also demonstrated an association between iri-
notecan and steatohepatitis [57,59]. The development of
steatohepatitis is significant because it has been associated
with hepatic insufficiency and failure, as well as death
after liver resection. Bevacizumab has demonstrated effi-
cacy at decreasing the oxaliplatin associated sinusoidal
injury and has demonstrated safety when discontinued
greater than 5 weeks prior to surgery [59]. However, bev-
acizumab has also been associated with gastrointestinal
perforations and bleeding complications [61,62]. There
has been additional concern regarding liver regeneration
after resection with the use of bevacizumab in those
patients undergoing PVE. However, it would appear that
bevacizumab does not significantly alter the hypertrophy
response of the liver following PVE [63]. As chemotherapy
regimen options expanded, it has become imperative to
consider each regimen's associated toxicities to best plan
the regimen type and duration of therapy so as to mini-
mize toxicity. Hence, a multidisciplinary approach with
medical oncology and surgeons in a tertiary care institu-
tion may be optimal for patient outcomes in light of the
considerations of chemotherapy, associated toxicities,
and timing of surgical intervention.
Non-Resectional Locoregional Therapy
Thermal ablation
Local therapy options use targeted energy to destroy
tumor cells. Such thermal ablation can be done by cool-
ing, in the case of cryoablation, or by heating tumor with
high-energy radio waves. Given the wider use of the latter,
we will focus our discussion on radiofrequency ablation
(RFA). The goal of RFA is to heat tumoral tissue and a mar-
gin of surrounding normal parenchyma to a point that
induces coagulative necrosis. This is done by insertion of
a needle-type electrode into tumor tissue with an alternat-
ing current that is generated between the implanted elec-
trode and a dispersive skin electrode/grounding pad,
resulting in ionic agitation, frictional heating, and ulti-
mately coagulation necrosis of the tumor tissue [64]. This
can be completed percutaneously, as an open surgical pro-
cedure, or laparoscopically and has been increasingly used
for patients that are high surgical risk or in situations
where preservation of normal hepatic parenchyma is par-
amount. Multiple studies have attempted to compare
ablation to resection for a variety of hepatic tumors, par-
ticularly CLM, to define its role in the treatment algo-
rithm. Most studies focus on local recurrence rates, and
have demonstrated wide variability from 1.7% to over
66.7% [65-72].
Several technical factors account for this wide variance in
local recurrence rates. These include tumoral factors, oper-
ator factors, and technical factors. Consistent throughout
the literature has been the impact of tumor size on local
recurrence rates. In a large retrospective study by Siper-
stein et al., 234 patients that underwent 292 ablations
were examined [73]. RFA of tumors >3 cm. resulted in
local recurrence rates of 28% while tumors ≤ 3 cm.World Journal of Surgical Oncology 2009, 7:72 http://www.wjso.com/content/7/1/72
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recurred locally in 20% (p = 0.07). Median survival for
those with >3 lesions was 17 months versus 27 months in
those patients with ≤ 3 lesions(p = 0.0018). Others have
demonstrated a similar negative impact of increasing
tumor size on the rate of local recurrence [74-78].
Similarly, local recurrence rates are influenced by
approach, with percutaneous approaches often being
associated with higher recurrence rates compared to lapar-
oscopic or open approaches [79-81]. Proximity to large
vessels resulting in a "heat sink" is another limitation of
ablation. The passage of blood through a large vessel in a
region to be ablated produces a local cooling effect below
the target temperature of 100°C. Perhaps more important
is the "energy sink" that results from the travel of electric
current from the energy source through the less resistant
blood vessel back toward the grounding pad, thus reduc-
ing the amount of energy delivered to the tumor [82,83].
In a study by Abdalla et al., they examined 418 patients
with curative intent for CLM, RFA was utilized as the sole
treatment in 57, while RFA was combined with resection
in 101 [71]. The remaining patients underwent resection
alone (N = 190) or no local therapy (N = 70). RFA alone
resulted in the highest rates of overall recurrence at any
site (84%), recurrence within the liver (44%), or true local
recurrence (9%) compared to recurrence rate of resection
alone (52%, 11%, 2%, respectively) or recurrence rates for
resection in combination with RFA (64% and 5% for over-
all and local recurrence, respectively). In patients with sin-
gle lesions, resection resulted in a significant survival
advantage over RFA alone. Noteworthy was that in spite of
the inferiority of RFA to resection, it did provide a signifi-
cant survival advantage over chemotherapy alone in the
70 patients where the operation was aborted (p = 0.0017).
Although this study attempted to make comparisons
between patients with similar tumor burden, the retro-
spective design cannot take into account intraoperative
decision making that potentially biases the data in favor
of resection. This underscores the need for prospective
studies to address this issue.
The next generation of ablation techniques attempts to
address many of the technical limitations described
above. Microwave ablation, as its names suggests, radiates
microwaves at 915 MHz from the active port of an
antenna placed within a tumor via a percutaneous, lapar-
oscopic, or open approach. While the technology works to
minimize the "heat sink" effect, it too is limited by many
of the same principles as RFA. Ianniti et al. examined this
technology with various liver tumors in 87 patients. They
undertook 94 ablation procedures in 87 patients for 224
tumors with local site recurrence of 2.7% and regional
recurrence in 43% [84]. Other ablative techniques are on
the horizon but are, as of yet, unproven in CLM including
2.4 GHz microwave ablation, irreversible electroporation
and laser induced thermotherapy(LITT) which utilizes
photons from low intensity lasers(diode, N-Yag) that are
then absorbed by chromophores within cells and then
converted to heat to induce tumor ablation [85,86].
Regional Therapies
Patients with multifocal CLM who are unfit for surgery or
have tumor burden/distribution not amenable to resec-
tion or ablation are potentially candidates for liver-
directed therapy. Such regional therapy options include
transarterial chemoembolization (TACE), radioemboliza-
tion or selective internal radiation therapy(SIRT), and
hepatic artery infusion pump (HAIP).
HAIP is a technology that allows for regional delivery tra-
ditionally of high dose floxuridine(FUDR) as well as other
chemotherapy regimens into CLM. Fahy et al. reviewed
multiple trials studying HAIP as neoadjuvant or adjuvant
chemotherapy [87]. That review highlighted the limita-
tions of multiple small trials with variable chemotherapy
regimens employed in a neoadjuvant setting with
response rates ranging from 16-82% with variable rates of
conversion from unresectable to resectable disease from
3-47%. Thus, it remains unclear as to the efficacy of HAIP
until a large, randomized trial is performed.
In the adjuvant setting, trials suggest an improved disease
free survival (DFS) with the use HAIP chemotherapy.
Kemeny et al. examined adjuvant HAIP chemotherapy
with systemic(combined) versus systemic therapy
alone(monotherapy) with encouraging results [88]. With
median follow up of 10.3 years, combined therapy
resulted in an increased PFS of 31.3 months compared to
17.2 months with monotherapy(p = 0.02). As well,
median hepatic PFS was not yet reached in the combined
group compared to 32.5 months in the monotherapy
group (p < 0.01). With combined therapy, the median OS
was 68.4 months compared to 58.8 months in the mono-
therapy group(p = 0.10), there appeared to be improved
long-term outcome with 10-year survival rates of 38.7%
and 16.3%, respectively. Hence, this suggests that the use
of HAIP as an adjuvant chemotherapy does confer a ben-
efit in PFS, survival free of liver progression, and potential
benefit to long-term outcome.
It is important to remember that the use of HAIP does
have inherent associated risks and complications. HAIP
requires an operation to place the catheter within the
common hepatic artery. With that, there is a moderate
complication rate of which early complications are
known to include extrahepatic or incomplete perfusion,
gastritis, ulcers, arterial/catheter thrombosis, and infec-
tion. Late complications include hemorrhage and biliary
sclerosis.World Journal of Surgical Oncology 2009, 7:72 http://www.wjso.com/content/7/1/72
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Selective internal radiation therapy (SIRT) has been a
fairly recent technology that has been used for the
regional delivery of radioactive beads simultaneously to
multiple tumors. Millions of microscopic radioactive
spheres are delivered via a catheter placed in the femoral
artery into the hepatic artery. Each sphere (approximately
35 microns in size) is bonded to yttrium-90(90Y) which is
a beta particle emitter with a half-life of 64 hours and pen-
etration of only two to three millimeters. These beads are
small enough to penetrate the microvasculature of the
tumors but large enough to lodge in the precapillary arte-
rioles. Slow decay of the 90Y results in tumoral radiation
as high as 150-200 Gy with relatively little radiation (i.e.
<45 Gy) to normal hepatic parenchyma.
Candidates for SIRT are considered if they have good
hepatic reserve, patency of the main portal vein, and less
than 10% hepato-pulmonary shunting of blood as deter-
mined by a pre-procedure tagged macroaggregated albu-
min (Tc99-MAA) scan. Hepatic arteriogram is first
undertaken with embolization of visceral vessels as
needed to prevent microsphere spread to extrahepatic
normal tissues. Hepato-pulmonary shunting >20% pro-
hibits SIRT due to risk of radiation pneumonitis whereas
shunting between 10-20% requires reduction in calcu-
lated dosimetry, and <10% is safe to proceed. Rare com-
plications include radiation induced liver disease,
gastrointestinal ulceration, and hemorrhage [89-91].
SIRT is still a novel therapy being employed so there are
limited studies at this point examining its efficacy,
response, and toxicity. Kennedy et al. examined 208
patients that received salvage therapy due to CLM refrac-
tory to oxaliplatin and irinotecan therapy [92]. This study
found that those patients who responded had median sur-
vival of 10.5 months versus 4.5 months in nonresponders
without any procedure related deaths or liver failure. Par-
tial radiographic response was noted by CT scan in 35%
and by PET scan in 91% with a biochemical response in
CEA reduction seen in 70%.
Four prospective trials of SIRT for CLM are completed or
ongoing [90]. A phase III trial examining SIRT + hepatic
artery chemotherapy (HAC) vs. HAC alone was conducted
in 74 patients. The complete response(CR) and partial
response(PR) and PFS was increased for combination
therapy (44% and 15.9 months) versus HAC alone
(17.6% and 9.7 months)(p = 0.01) suggestive of a survival
benefit for the addition of SIRT.
A small randomized phase II/III trial examining the use of
SIRT and 5-FU/leucovorin versus chemotherapy alone in
21 patients yielded promising results [90]. The combina-
tion therapy demonstrated increased PFS (18.6 vs. 3.4
months, p < 0.001) and OS(29.4 versus 12.8 months, p =
0.02) compared to chemotherapy alone.
A small phase I trial from Australia and the United King-
dom by Sharma et al. examined 20 unresectable, chemo-
therapy-naive CLM patients using FOLFOX4 and SIRT
with dose escalation of oxaliplatin to standard 85 mg/
m2[93]. Median PFS was 9.3 months and median time to
hepatic progression was 12.3 months. Two patients pro-
ceeded to partial liver resection.
An additional dose escalation phase I trial by Goldstein et
al. examined combination therapy with SIRT and irinote-
can in 25 irinotecan-naïve patients who had failed chem-
otherapy previously [94]. Dose escalation to 100 mg/m2
with SIRT was administered as tolerated with acceptable
toxicity. Results demonstrated 9/17 patients with partial
response, with median time to hepatic progression of 7.5
months and median OS of 12 months.
Stubbs et al. examined 50 patients with advanced, unre-
sectable colorectal liver metastases and SIRT [95]. Patients
tolerated SIRT with no associated mortality but with some
treatment associated morbidity, most notably a 12% duo-
denal ulceration rate. Serial CEA levels and radiographic
response were followed. Median CEA at 1 and 2 months
post-treatment were 19 and 12% of baseline, respectively.
A statistically significant survival benefit was seen in those
patients without extrahepatic disease in which they had
median survival of 17.5 months with estimated survival of
79.2%, 66.7%, 55.9%, 25.2%, and 16.8% at 6, 12, 18, 24,
and 30 months, respectively when compared to those
patients with extrahepatic disease. Tumor marker decline
was observed in more than 90% of patients after a single
treatment and survival times, particularly for those who
did not develop extrahepatic metastases for some time,
appear to be prolonged.
In an additional study, Stubbs et al. examined 100
patients with advanced, unresectable colorectal liver
metastases [96]. SIRT was performed and median CEA lev-
els three months after treatment were 18% of the original
baseline CEA level. Radiographically, only 5/80(6.25%)
patients demonstrated progression of disease. Patients
with tumor marker response demonstrated increased sur-
vival as well suggesting a benefit of SIRT in this patient
population.
Conclusion
The management of CLM has evolved as therapeutic
options have continued to expand and grow. Traditional
dogma that had once previously limited treatment for the
most part is no longer valid. Many characteristics that
used to be considered contraindications to surgical inter-
vention are no longer substantiated. Modern cytotoxicWorld Journal of Surgical Oncology 2009, 7:72 http://www.wjso.com/content/7/1/72
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chemotherapy along with addition of biologic agents has
generated improvement in response, survival, and the fea-
sibility of offering patients various surgical and locore-
gional interventions. As surgical intervention has been
made more feasible by modern day chemotherapy,
improved surgical techniques and adjuncts to resec-
tion(e.g. RFA, PVE) has facilitated more patients being
offered potentially curative therapy. Additionally, locore-
gional therapies including TACE, SIRT, and HAIP remain
reasonable options for high risk patients and those with
unresectable disease. On the whole, the management of
CLM has seen great strides made and we continue to
evolve the therapeutic options and approaches with
improvement in patient outcomes. Therefore, in order to
provide optimal outcomes for patients with CLM, it is
imperative to consider all treatment options available
based on each patient's clinical picture and best care may
be undertaken in a tertiary care center where a multidisci-
plinary approach can be offered and pursued with collab-
oration of surgeons, medical oncologists, and
interventional radiologists.
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